Li, Ji-Liang - Plymouth University

个人简介

Role Professor & Chair of Cancer Sciences Plymouth University Peninsula Schools of Medicine and Dentistry Qualifications PhD, Molecular Medicine, London School of Tropical Medicine & Hygiene, University of London, UK (1997) MMed, Medicine, Sun Yat-Sen University College of Medicine, Guangzhou, China MD, Medicine, Suzhou Medical College, Suzhou, China Previous positions 2007–2015: Deputy Lab Head, Weatherall Institute of Molecular Medicine, University of Oxford, UK; 2002–2007: Tenured Staff Scientist/Deputy Lab Head, Cancer Research UK (CRUK), UK; 1999–2002: Research Fellow, Imperial Cancer Research Fund (ICRF), UK; 1996–1999: Postdoc Research Associate, Department of Biochemistry, University of Oxford, UK

研究领域

My research interest focuses on tumour microenvironment and translational cancer medicine. By employing a variety of approaches including molecular biology, cell biology, immunology, proteomics, next-generation sequencing, bioinformatics, animal models, human tumour samples and relevant clinical data, my research is dedicated to delineate mechanisms on how key molecules (such as microRNAs, lncRNAs, and RN181 E3 ligase), signalling pathways (such as Notch signalling), tumour cells, and tumour stromal cells (such as endothelial cells, infiltrating lymphocytes, tumour-associated macrophages, and tumour-associated fibroblasts) in tumour microenvironment regulate tumour growth and metastasis and tumour response to therapeutic interventions (in particular, cross-interactions among radiotherapy, chemotherapy, targeted therapy and immunotherapy). My aims are (1) to dissect mechanisms of tumour migration, invasion and metastasis, (2) to develop novel therapeutic targets or biomarkers, and (3) to improve therapeutic efficacy by optimal combinations of radiotherapy, chemotherapy, targeted therapy, or immunotherapy. Primary cancer types I am currently working on include, but not limit to, brain tumour (eg, diffuse gliomas), gastrointestinal tumour (eg, gastric, colorectal and hepatic cancer), and head & neck cancer (eg, nasopharyngeal carcinoma). Tumour Microenvironment and Translational Cancer Medicine Cancer Immunology Tumour associated macrophage Tumour invasion and metastasis Hypoxia and angiogenesis pathways Notch signalling in cancer biology Cancer-associated lncRNAs and MicroRNAs Tumour resistance to therapeutic treatments Optimal combination therapy Preclinical mouse tumour models

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

da Motta, L.L., Ledaki, I., Purshouse, K., Haider, S., De Bastiani, M.A., Baban, D., Morotti, M., Steers, G., Wigfield, S., Bridges, E., Li, J.L., Knapp, S., Ebner, D., Klamt, F., Harris, A.L., McIntyre, A. (2016): The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer. Oncogene, Jun 13. doi: 10.1038/onc.2016.184. [Epub ahead of print] McIntyre, A., Hulikova, A., Ledaki, I., Snell, C., Singleton, D., Steers, G., Seden, P., Jones, D., Bridges, E., Wigfield, S., Li, J.L., Russell, A., Swietach, P. and Harris, A.L. (2016): Disrupting hypoxia-induced bicarbonate transport acidifies tumor cells and suppresses tumor growth. Cancer Research, Jul 1; 76(13):3744-3755. doi: 10.1158/0008-5472.CAN-15-1862. Fan, S.J., Snell, C., Turley, H., Li, J.L,, McCormick, R., Perera, S.M., Heublein, S., Kazi, S., Azad, A., Wilson, C., Harris, A.L., Goberdhan, D.C. (2016): PAT4 levels control amino-acid sensitivity of rapamycin-resistant mTORC1 from the Golgi and affect clinical outcome in colorectal cancer. Oncogene, Jun 9; 35(23):3004-3015. doi: 10.1038/onc.2015.363. He, P., Wang, S., Zhang, X., Gao, Y., Niu, W., Dong, N., Shi, X., Geng, Y., Ma, Q., Li, M., Jiang, B. and *Li, J.L. (2016): Tspan5 is an independent favourable prognostic factor and suppresses tumour growth in gastric cancer. Oncotarget, May 20; 7(26): 40160-40173. doi: 10.18632/oncotarget.9514. (*corresponding author) Chen, Y., Wang, S., Liu, T., Wu, Y., *Li, J.L., Li, M. (2016): WAP four-disulfide core domain protein 2 gene (WFDC2) is a target of estrogen in ovarian cancer cells. J Ovarian Res., Feb 29; 9:10. doi: 10.1186/s13048-015-0210-y. (*corresponding author) He, B., Xiao, Y.F., Tang, B., Wu, Y.Y., Hu, C.J., Xie, R., Yang, X., Yu, S.T., Dong, H., Zhao, X.Y, *Li, J.L. and Yang, S.M. (2016): hTERT mediates gastric cancer metastasis partially through the indirect targeting of ITGB1 by microRNA-29a. Scientific Reports, Feb 23; 6:21955. doi:10.1038/srep21955. (*corresponding author). Yang, J., Tahan, A.A., Jones, D.T., Buffa, F.M., Bridges, E., Interiano, R.B., Qu, C., Vogt, N., Li, J.L. et al. (2015): Estrogen receptor-α directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer. Proc Natl Acad Sci U S A., Dec 8; 112(49): 15172-15177. doi: 10.1073/pnas.1422015112. Ramcharan, R., Aleksic, T., Gao, S., Kamdoum, W.P., Tanner, J., Bridges, E., Asher, R., Watson, A.J., Margison, G.P., Woodcock, M., Repapi, E., Li, J.L., Middleton, M.R. and Macaulay, V.M. (2015): IGF-1R inhibition induces schedule-dependent sensitization of melanoma to temozolomide. Oncotarget, Nov 24; 6(37): 39877-39890. doi: 10.18632/oncotarget.5631. Ledaki, I., McIntyre, A., Wigfield, S., Buffa, F., McGowan, S., Baban, D., Li, J.L. and Harris, A.L. (2015): Carbonic anhydrase IX induction defines a heterogeneous cancer cell response to hypoxia and mediates stem cell-like properties and sensitivity to HDAC inhibition. Oncotarget, Aug 14; 6(23):19413-19427. DOI: 10.18632/oncotarget.4989 Cai, L., Ye, Y., Jiang, Q., Lyu, X., Chen,Y., Li, J., Wang, S., Liu, T., Yao, K., *Li, J.L. and Li, X. (2015): Epstein-Barr virus-encoded microRNA BART1 induces tumour metastasis by regulating PTEN-dependent pathways in nasopharyngeal carcinoma. Nature Commun., July 2; 6:7353. doi:10.1038/ncomms8353. (*corresponding and co-senior author).